Immix Biopharma, Inc. (NASDAQ:IMMX)

ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site

Format

PNG

Immix Biopharma, Inc.